Correlation Between 99mTc-HYNIC-octreotide SPECT/CT Somatostatin Receptor Scintigraphy and Pathological Grading of Meningioma

Overview

Journal J Neurooncol

Publisher Springer

Date 2013 May 10

PMID 23657621

Citations 6

Authors

Shengjun Wang

Weidong Yang

Jinglan Deng

Jianning Zhang

Fucheng Ma

Jing Wang

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to explore the association of (99m)Tc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy (SRS) with the pathological grading and expression of somatostatin receptor 2 (SSTR2) for meningioma, and to define possible roles of SRS in the pathological grading of meningioma. Thirty patients with meningiomas diagnosed by MRI and treated with (99m)Tc-HYNIC-octreotide SPECT/CT SRS. Meningioma tissues were obtained from analyzing pathological grading and measuring the expression of SSTR2 with immunohistochemical staining. The meningioma side (T) to the contralateral side (NT) ratios (T/TN) of radioactive counts were calculated to investigate their association with the pathological grading of meningioma and the expression of SSTR2. All 30 cases showed high meningioma radioactivity accumulation using SRS with a sensitivity of 100 %, while CT scans only detected 25 cases with a sensitivity of 83 %. Twenty cases with grade I meningioma had a T/NT ratio of 3.80 ± 1.67, which was significantly lower than the other 10 cases (9.57 ± 3.78) with a grade II meningioma (P < 0.01). All meningiomas expressed SSTR2 as detected by immunohistochemical staining, and the T/NT ratio was positively associated with the pathological grading of meningioma and the expression of SSTR2 (with r of 0.784 and 0.805, respectively). (99m)Tc-HYNIC-octreotide SPECT/CT SRS is a sensitive technique for detecting meningioma, and the T/NT ratio of the SRS data closely correlates with the pathological grade of meningioma and the expression of SSTR2.

Citing Articles

Risk factors associated with higher WHO grade in meningiomas: a multicentric study of 552 skull base meningiomas.

May M, Sedlak V, Pecen L, Priban V, Buchvald P, Fiedler J Sci Rep. 2025; 15(1):3715.

PMID: 39880897 PMC: 11779799. DOI: 10.1038/s41598-025-87882-z.

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.

Albert N, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer J Eur J Nucl Med Mol Imaging. 2024; 51(12):3662-3679.

PMID: 38898354 PMC: 11445317. DOI: 10.1007/s00259-024-06783-x.

Radioligand therapies in meningioma: Evidence and future directions.

Mair M, Tabouret E, Johnson D, Sulman E, Wen P, Preusser M Neuro Oncol. 2024; 26(Supplement_9):S215-S228.

PMID: 38702966 PMC: 11631075. DOI: 10.1093/neuonc/noae069.

The Simpson Grading: Is It Still Valid?.

Chotai S, Schwartz T Cancers (Basel). 2022; 14(8).

PMID: 35454912 PMC: 9031418. DOI: 10.3390/cancers14082007.

Somatostatin Receptors in Human Meningiomas-Clinicopathological Aspects.

Tollefsen S, Jarmund A, Ytterhus B, Salvesen O, Mjones P, Torp S Cancers (Basel). 2021; 13(22).

PMID: 34830858 PMC: 8616360. DOI: 10.3390/cancers13225704.

References

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H, Schwaiger M . Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2008; 36(1):48-52. DOI: 10.1007/s00259-008-0944-5. View

Decristoforo C, Melendez-Alafort L, Sosabowski J, Mather S . 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med. 2000; 41(6):1114-9. View

Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard J, Wassef M . Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003; 44(11):1767-74. View

Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J . Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008; 27(5):334-45. DOI: 10.5414/npp27334. View

Kwekkeboom D, Krenning E . Somatostatin receptor imaging. Semin Nucl Med. 2002; 32(2):84-91. DOI: 10.1053/snuc.2002.31022. View

Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P . Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging. 2005; 32(12):1440-51. DOI: 10.1007/s00259-005-1875-z. View

Volante M, Brizzi M, Faggiano A, La Rosa S, Rapa I, Ferrero A . Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007; 20(11):1172-82. DOI: 10.1038/modpathol.3800954. View

Haldemann A, ROSLER H, Barth A, Waser B, GEIGER L, Godoy N . Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med. 1995; 36(3):403-10. View

Perry A, Gutmann D, Reifenberger G . Molecular pathogenesis of meningiomas. J Neurooncol. 2005; 70(2):183-202. DOI: 10.1007/s11060-004-2749-0. View

10.

Schulz S, Helmholz T, Schmitt J, Franke K, Otto H, Weise W . True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat. 2002; 72(3):221-6. DOI: 10.1023/a:1014972520302. View

11.

Nathoo N, Ugokwe K, Chang A, Li L, Ross J, Suh J . The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2006; 81(2):167-74. DOI: 10.1007/s11060-006-9210-5. View

12.

Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N . Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med. 1998; 25(7):675-86. DOI: 10.1007/s002590050269. View

13.

Willis J, Smith C, Ironside J, Erridge S, Whittle I, Everington D . The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol. 2005; 31(2):141-9. DOI: 10.1111/j.1365-2990.2004.00621.x. View

14.

Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R . Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998; 76(5):620-7. DOI: 10.1002/(sici)1097-0215(19980529)76:5<620::aid-ijc2>3.0.co;2-s. View

15.

Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V . Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004; 66(1-2):155-66. DOI: 10.1023/b:neon.0000013498.19981.55. View

16.

Klutmann S, Bohuslavizki K, Brenner W, Behnke A, Tietje N, Kroger S . Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med. 1998; 39(11):1913-7. View

17.

Hasseleid B, Meling T, Ronning P, Scheie D, Helseth E . Surgery for convexity meningioma: Simpson Grade I resection as the goal: clinical article. J Neurosurg. 2012; 117(6):999-1006. DOI: 10.3171/2012.9.JNS12294. View

18.

Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A . Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006; 65(1):222-7. DOI: 10.1016/j.ijrobp.2005.12.006. View

19.

Reubi J, Waser B, Schaer J, Laissue J . Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001; 28(7):836-46. DOI: 10.1007/s002590100541. View

20.

Mezi S, Primi F, Orsi E, Capoccetti F, Scopinaro F, Schillaci O . Somatostatin receptor scintigraphy in metastatic breast cancer patients. Oncol Rep. 2004; 13(1):31-5. View